Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after ... GIP agonist as an option alongside diet and exercise for patients whose ...

More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more than half of those aged over 30 who have the condition are not receiving ...

with Zepbound and diabetes drug Mounjaro — the active ingredient in both is tirzepatide, a GLP-1 receptor agonist — missing Wall Street estimates by almost $900 million in sales. Eli Lilly ...

She felt miserable on the low-carb diet she had to switch to and it left a ... Drugs such as Novo Nordisk's Ozempic and Eli ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Rybelsus: Novo Nordisk’s name-brand version of oral semaglutide tablets to help improve blood sugar levels (along with diet ...